Podcasts about stroke unit

ROMA (ITALPRESS) - “La sanità regionale si sta curando, cresce e dà risposte. Il San Camillo è un hub importante per la rete stroke. Salva vite e salva la qualità della vita”, ha detto il Presidente della Regione Lazio Francesco Rocca in occasione dell'inaugurazione all'ospedale San Camillo della Stroke Unit e di due reparti di terapia intensiva e semi intensiva. “ È una bella giornata per la sanità laziale che si sta curando, cresce e dà risposte ai cittadini” ha aggiunto (ITALPRESS)xl5/trl/mrv

ROMA (ITALPRESS) - “La sanità regionale si sta curando, cresce e dà risposte. Il San Camillo è un hub importante per la rete stroke. Salva vite e salva la qualità della vita”, ha detto il Presidente della Regione Lazio Francesco Rocca in occasione dell'inaugurazione all'ospedale San Camillo della Stroke Unit e di due reparti di terapia intensiva e semi intensiva. “ È una bella giornata per la sanità laziale che si sta curando, cresce e dà risposte ai cittadini” ha aggiunto (ITALPRESS)xl5/trl/mrv

Every year, more than 12 million people suffer from strokes. With 6.5 million dead and many left with permanent disability, it is one of the leading causes of death and disability worldwide. Today, we'll learn about the stroke pathway and secondary stroke risk as well as the underlying diseases that are connected to stroke and how they can be identified and treated.In this episode, host Wiebke Plenkers, product line head for ON THE SPOT, Siemens Healthineers global mobile CT solutions, is joined by Mira Katan, MD, head of Stroke Unit and deputy head of Acute Neurology at University Hospital Basel in Switzerland and Carlos Molina, MD, head of Neurology Section and director of Stroke Unit at Barcelona's Vall d'Hebron Research Institute.What You'll Learn in This Episode:The pathway for an incoming patient after it is determined that they are suffering from a strokeDetermining the type and severity of the stroke is an important deciding factor for successful treatmentModern imaging techniques support in the identification between an ischemic or hemorrhagic stroke Secondary stroke events are a significant risk for many stroke patients Educating patients is key in preventing secondary stroke eventsImplementation of telemedicine is just one of the advances that might improve outcomes for stroke patients in the futureConnect with Wiebke Plenkers•LinkedInConnect with Mira Katan•LinkedInConnect with Carlos Molina•LinkedIn Hosted on Acast. See acast.com/privacy for more information.

Alle zwei Minuten erleidet in Deutschland ein Mensch einen Schlaganfall. Weltweit ist es laut WHO sogar die zweithäufigste Todesursache. Dr. Petra Mummel aus der MEDICLIN Hedon Klinik erklärt in dieser Folge unter anderem, welche Symptome ein Schlaganfall haben kann und wie wir bei einem Verdacht auf Schlaganfall handeln sollten. Sie ist Ärztliche Direktorin und Chefärztin für Akutneurologie und Neurologische Frührehabilitation.

Dr. Saad Mir,  is an Assistant Professor of Clinical Neurology at Weill Cornell Medical College and Assistant Attending Neurologist at New York-Presbyterian Hospital, speaks about the use of mobile stroke units at NYP on Newsline with Brigitte Quinn.  

230613PC Hamster im hineren StromgebietMensch Mahler am 13. Juni 2023Ich liebe die Bücher von Joachim Meyerhoff. Habe sie alle gelesen und „wann wird es endlich so, wie es nie war“ habe ich im Kino gesehen. Alle 5 Bücher von ihm sind autobiografisch. Und sein neuestes, es heißt „Hamster im hinteren Stromgebiet“ hat mich deshalb erwischt, weil es auch meine Geschichte erzählt. Joachim Meyerhoff sah sich „aus heiterem Himmel“, wie man so sagt, im Krankenhaus auf der Stroke Unit. Schlaganfall. Er bescheibt auf 400 Seiten das, was er erlebt, gedacht, erinnert und phantasiert hat.Als ich im Herbst 2021 ins Krankenhaus eingeliefert wurde, Diagnose Krebs, habe ich dieselbe Zeit durchlebt. Alles zieht im Angesicht des möglichen Todes aus dem Unterbewussten kommend am Bewussten vorbei. Alle Erinnerungen, Ängste, gelebte und ungelebte Träume. Einer solche Krankheitszeit ist ein tiefer Einschnitt. Eine Zeit der Reinigung und der Besinnung aufs Wesentliche. Nicht, dass ich einem Menschen so etwas wünschen würde. Den Moment der Diagnose nach der OP: Herr Mahler, ein solches CAP-Syndrom ist in den meisten Fällen tödlich. Was ist das? Fragte ich. Cancer of unknown Primarius. Also Metastase mit unbekanntem Wirt.Ich war allein im Zimmer, meine Frau war zu Hause und wir haben die Nacht – an unerschiedlichen Orten – durch gebrüllt, geweint und gebetet.Bei Meyerhoff und Mahler ist die Geschichte zunächst gut ausgegangen. Vorläufig.Warum sie Hamster im hinteren Stromgebiet lesen sollten, auch wenn sie keine schwere Krankheit durchleiden müssen? Es hilft, das Leben neu zu sortieren. Sich auf das zu konzentrieren, was wirklich wesentlich ist. Jeden Tag so zu leben, als wäre es ihr letzter.Hamster im hinteren Stromgebiet von Joachim Meyerhoff ist erschienen im Verlag Kiepenheuer& Witsch. Hosted on Acast. See acast.com/privacy for more information.

Jede/r vierte unserer Landsleute erleidet in seinem Leben einen Schlaganfall. Welche Symptome bei einem Schlaganfall auftreten, wie sehr man das landläufige „Schlagerl“ ernst nehmen sollte und warum es tatsächlich bei der Rettungskette um Minuten geht, erklärt Univ.Prof. Prim. Dr. Andreas Kampfl, Leiter der Abteilung Neurologie und der Stroke Unit im Krankenhaus der Barmherzigen Schwestern Ried.

1. Thema Schlaganfall: OA Dr. Omid Hosseiny, Leitung Stroke Unit und Parkinson Ambulanz

2. Thema Parkinson: OA Dr. Omid Hosseiny, Leitung Stroke Unit und Parkinson Ambulanz

In the blink of an eye, I found myself flat on my back. The anxiety I felt was terrifying as they wheeled me to the Stroke Unit. Not another stroke! Really? Ehat is going on? God was with through every scary and painful second. Are you hiding His Word in your heart? --- Send in a voice message: https://anchor.fm/pleasingtothepotter/message

For Stroke Awareness Month this May, each episode we'll talk with professionals, doctors, researchers and therapists who work with stroke patients and in stroke science. Highlighting the people who work in stroke care, hearing their stories, why they chose their career paths, hopefully this encourages future generations of stroke professionals! Continuing this series, we spoke with Arianne Navarro, Staff Nurse for the Stroke Unit at Memorial Hermann Hospital in the Texas Medical Center. The Institute for Stroke and Cerebrovascular Disease (UTHealth Stroke Institute) http://www.utstrokeinstitute.com/ Hosts: Amy Quinn Twitter: @UTHealthStroke Instagram: @UTHealthStroke Facebook: facebook.com/uthealthstroke Ideas and opinions are our own and this podcast is not a substitute for expert medical advice.

15 Prozent aller Corona-Infizierten leiden unter langfristigen Folgen der Infektion – selbst dann, wenn sie zunächst gar nicht akut krank waren. Auch bei Unternehmer Bernfried Fleiner hat Covid-19 Spuren hinterlassen. Im Podcast erzählt er von monatelangen Erschöpfungszuständen, Geruchs- und Geschmacksverlust und der Unterstützung durch die BG ETEM im Genesungsprozess: Da er sich nachweislich im Betrieb angesteckt hatte, stufte die BG seine Erkrankung als Arbeitsunfall ein, organisierte einen Post-Covid-Check und umfangreiche Rehamaßnahmen für Fleiner.Zweiter Gast von Moderatorin Katrin Degenhardt ist PD Dr. med. Kai Wohlfarth, Chefarzt der Klinik für Neurologie und fachübergreifende Frührehabilitation am BG Klinikum Bergmannstrost in Halle. Er erklärt, was die BG Kliniken tun, um Post-Covid-Erkrankten zu helfen und welche Rolle Führungskräfte im Genesungsprozess spielen. Außerdem berichtet er von seinen ganz persönlichen Erfahrungen mit den langfristigen Folgen von Covid-19.Die Gäste:Bernfried Fleiner ist Geschäftsführer des Maschinenbau-Unternehmens exaron GmbH aus Oberndorf. Er sagt: Mit Eigenverantwortung, Konsequenz und Engagement können Post-Covid-Betroffene wieder ins Leben finden – und ihre Führungskräfte sollten sie dabei mit Verständnis und Flexibilität unterstützen.PD Dr. med. Kai Wohlfarth ist Direktor der Kliniken für Neurologie, Frührehabilitation und Stroke Unit der BG Klinik Bergmannstrost in Halle und Teil des Arbeitskreises Neurologie der BG Kliniken. Sein Rat an Führungskräfte, die die Wiedereingliederung von Post-Covid-Erkrankten im Unternehmen begleiten: Nicht nach Schema F vorgehen und den Betroffenen Zeit geben, um sowohl privat als auch beruflich wieder in den Alltag zurück zu finden.Das Thema:Hier gibt es den Artikel über Bernfried Fleiner aus der „etem“, Ausgabe 2/2022. In derselben Ausgabe: Unter welchen Voraussetzungen Covid-19 als Berufskrankheit oder Arbeitsunfall anerkannt wird.Informationen zum Post-Covid-Programm der BG Kliniken gibt es hier.Die BG ETEM informiert an dieser Stelle über den Versicherungsschutz im Zusammenhang mit dem Coronavirus und Covid-19.Um auf die Website der BG Kliniken zu gelangen, bitte diesem Link folgen.Themenseite zu Post-Covid der Deutschen Gesetzlichen Unfallversicherung (DGUV): Klicken Sie hierDas Magazin:Die aktuelle Ausgabe steht immer unter etem.bgetem.de bereit.Sie wollen ältere Ausgaben lesen? Zum Archiv bitte hier entlang.

In this episode, we sat down with Dr. Suja Rajan following her groundbreaking presentation on the cost-effectiveness of mobile stroke units at the 2022 International Stroke Conference in New Orleans. Dr. Rajan and co-researchers aimed to prove “if outcome improvements associated with MSUs justify [an] increase in costs, thereby making MSUs cost effective, or if the outcome improvements lead to follow-up cost reductions thereby making MSUs cost-saving.” https://www.hmpgloballearningnetwork.com/site/neuro/conference-coverage/mobile-stroke-unit-utilization-cost-effective This was the first study that provided an economic evaluation using 1-year follow-up data on the cost-effectiveness of MSUs. Dr. Suja S. Rajan is a Health Economist and Econometrician, and is currently an Associate Professor at the School of Public Health, UT Health in Houston. Dr. Rajan's research interests include women's health, stroke and cancer health outcomes research, determining the effect of socio-economic determinants of health, identification and resolution of racial-ethnic, socio-economic and gender disparities, evaluating programs that address these disparities, and conducting cost-effectiveness and cost-benefit evaluations to establish the business case for medical interventions. Twitter: @UTHealthStroke Instagram: @UTHealthStroke Facebook: facebook.com/uthealthstroke Ideas and opinions are our own and this podcast is not a substitute for expert medical advice. About StrokeBusters is a podcast series of recorded conversations on the topic of stroke and cerebrovascular disease. Based in the Texas Medical Center, the largest medical center in the world, we tap into our local network of astonishing leaders in healthcare and medicine to discuss the latest and most exciting news on stroke. Throughout this ten-episode series, we connect with UTHealth physicians and researchers, many of who are experts in their field, to discuss their practice, cutting-edge research, and medical care. Who We Are The Institute for Stroke and Cerebrovascular Disease, better known as the Stroke Institute, serves as a multi-disciplinary hub for research and best practices in stroke recovery, stroke prevention, services, population health, and vascular dementia. We are one of the most active research and clinical programs in the country, the first Comprehensive Stroke Center in the state, and launched the first Mobile Stroke Unit in the nation. Our stroke program, founded by Dr. James Grotta in 1979, specializes in stroke epidemiology, clinical trial design, and basic science. We train the next generation of revolutionary academics and leaders in cerebrovascular disease through our NINDS-funded fellowship programs. Contact For more information or if you have any questions, please contact us at info.uthiscd@gmail.com

Jedes Jahr erleiden etwa 200.000 Deutsche einen Schlaganfall. Dann ist schnelle Hilfe gefragt. In vielen Kliniken gibt es Stroke Units, also Spezialstationen, dafür. Warum nicht in Dessau, fragt ein Hörer.

„Der Schlaganfall ist nach wie vor die dritthäufigste Todesursache in Deutschland“, warnt Professor Dr. Joachim Röther, Chefarzt der Neurologischen Abteilung mit überregionaler „Stroke Unit“ an der Asklepios Klinik Altona. Welche Formen man unterscheidet, wie man vorbeugt und therapiert, erklärt der Experte in der aktuellen Folge.

Sven Höchenberger ist Pfleger auf der Station 19.1 - der Stroke Unit mit dem Schwerpunkt neurologische Erkrankungen im Klinikum Osnabrück. Das Klinikum hat 16 neurologische Stroke-Betten und beherbergt damit eine der größten Stroke Units in ganz Deutschland. Hier werden ausschließlich Schlaganfall-Patienten behandelt. Wieso sich Schlaganfälle zu einer wahren Volkskrankheit entwickelt haben, warum es bei Patienten mit einem Schlaganfall besonders wichtig ist, schnell zu handeln und was der FAST-Test ist, hört ihr in der neuen Folge Lauschvisite. Jetzt reinlauschen!

On Episode 8 of the Stroke Alert Podcast, host Dr. Negar Asdaghi highlights two articles from the September 2021 issue of Stroke: “Risk of Fractures in Stroke Patients Treated With a Selective Serotonin Reuptake Inhibitor” and “Carotid Plaques From Symptomatic Patients Are Characterized by Local Increase in Xanthine Oxidase Expression.” She also interviews Drs. Jukka Putaala and Markku Kaste about their article “Should Tenecteplase be Given in Clinical Practice for Acute Ischemic Stroke Thrombolysis?”. Dr. Negar Asdaghi:         1) Are we ready to say goodbye to our old friend alteplase and replace it with a new one, tenecteplase, for acute stroke thrombolysis? 2) Does treatment of depression with SSRIs increase the risk of fractures in stroke patients? 3) When it comes to carotid intervention, should we continue offering treatment based on the degree of luminal stenosis, or are there better biomarkers in the horizon? These are some of the questions that we'll tackle in today's podcast. We're covering the best in Stroke. Stay with us. Dr. Negar Asdaghi:         Welcome back to Stroke Alert Podcast. My name is Negar Asdaghi. I'm an Associate Professor of Neurology at the University of Miami Miller School of Medicine and your host for the monthly Stroke Alert Podcast. For the September 2021 podcast, we have an exciting program where we discuss some of the controversies in stroke therapies. The September issue also contains a Focused Update with a set of articles and comprehensive reviews on the topic of genetics and stroke, organized by Professor Martin Dichgans, which I encourage you to review in addition to our podcast today. Later in today's podcast, I have the pleasure of interviewing Drs. Putaala and Kaste, from Helsinki Institute, to help us with a burning question of whether there's enough evidence now to use tenecteplase instead of alteplase for ischemic stroke thrombolysis. But first with these two articles. Dr. Negar Asdaghi:         Over a third of stroke survivors either have depressive symptoms or a formal diagnosis of depression. Selective serotonin reuptake inhibitors, or SSRIs, are the mainstay of depression treatment and the most common antidepressants prescribed in the U.S. In addition, in 2011, we had the results of the FLAME trial suggesting that early poststroke treatment with fluoxetine, a commonly prescribed SSRI, improves motor recovery and functional independence in stroke patients with motor deficit. Though these results were not replicated in the subsequent larger FOCUS trial, the use of SSRIs poststroke dramatically increased over the past decade. So what are the side effects of using SSRIs poststroke? It's a known fact that adult stroke survivors are more likely to experience bone fracture, and that there's some evidence that SSRIs may increase this risk. Dr. Negar Asdaghi:         So, in the current issue of the journal, Dr. Graeme Hankey and Joshua Jones, from Faculty of Health and Medical Sciences, University of Western Australia, in Perth, and colleagues aimed to answer this question with a systematic review and meta-analysis of randomized controlled trials that included an SSRI treatment for an adult patient with a previous hemorrhagic or ischemic stroke and included incident fractures, either as a primary or secondary study outcome, amongst other criteria. So they found four randomized controlled trials that fulfilled their research criteria. Three of them looked at the effects of fluoxetine, used at a dose of 20 mg per day for six months duration, on functional recovery and outcomes after stroke. And one trial, which has studied neuroregeneration in vascular protection by citalopram, either at a 10 mg or 20 mg daily dose also for six months duration, in patients with acute ischemic stroke. So three studies included with fluoxetine and one study included citalopram. Dr. Negar Asdaghi:         So, what they found was that although the risk of falls, seizures and recurrent stroke were not statistically increased with SSRI treatment, it was actually a significant increased risk of fractures with a risk ratio of 2.36 in patients treated with SSRI as compared to the placebo. Now, how the SSRIs will increase the risk of fractures is still unknown. There are multiple postulated mechanisms that are discussed in the paper, such as SSRIs potentially increasing spastic motor activity, causing orthostatic hypotension, dizziness, delayed reaction time or temporary imbalance or sleep disorders. But the most important mechanism to keep in mind is the possibility of SSRIs lowering bone mineral density. It's also important to note that the duration of exposure to SSRIs is an important predictor of factors. It's worth noting that the usual SSRI exposure in patients with the primary diagnosis of depression is a lot longer than the exposure time in these trials. Dr. Negar Asdaghi:         So, what are the top two takeaway points for stroke physicians? Number one: Fluoxetine and citalopram SSRIs, used for six months poststroke, double the risk of fracture as compared to placebo in this meta-analysis. Number two: While the mechanism of this association is still debated, fracture prevention should be an important discussion point when considering prescribing an SSRI to stroke patients. Dr. Negar Asdaghi:         We all know that carotid disease is a major cause of ischemic stroke. Now we have to keep in mind that the bulk of the literature in carotid disease are practically concentrated on the association between the degree of luminal stenosis and the risk of recurrent stroke. So, in practice, we constantly counsel and discuss risk of future ischemia in symptomatic and asymptomatic carotid disease based on the degree of stenosis that's less than 50%, or between 50% to 70%, or over 70%. Dr. Negar Asdaghi:         But what if we learn that some plaques can be active despite causing small or little stenosis? And conversely, some may be active despite being very large. There seems to be a growing literature that much of the recurrent strokes are occurring in destabilized plaques. And it turns out that there are actually biomarkers that could cause this destabilization, and we can actually measure them. Xanthine oxidase, or XO, is one of these biomarkers. XO is a key enzyme involved in degradation of purine into uric acid. Now I'm trying to simplify a complex subject here. Xanthine oxidase oxidizes the conversion of hypoxanthine into xanthine and xanthine into uric acid. Along the way, it also does create a whole bunch of reactive oxygen species such as superoxide and hydrogen peroxide, which can create tissue damage. Dr. Negar Asdaghi:         Now, how is XO and serum uric acid levels related to carotid disease? Well, it turns out that XO is enhanced in carotid arteries with evidence of atherosclerosis. Better yet, in animal models, inhibition of XO is associated with reduction in progression of atherosclerosis. So, in the current issue of the journal, Drs. Morsaleh Ganji and Valentina Nardi, from Departments of Cardiovascular Medicine and Anatomic Pathology of Mayo Clinic in Rochester, Minnesota, and colleagues set out to investigate whether carotid plaques from symptomatic patients had increased expression of xanthine oxidase than their asymptomatic counterparts. So, what they did was they looked at 88 patients undergoing carotid endarterectomy for symptomatic or asymptomatic carotid disease, part of the routine clinical practice, and then measured the XO expression by immunohistochemical staining in CA obtained specimens. Dr. Negar Asdaghi:         In addition, they collected a number of serum samples and other demographics and vascular risk factors from the participating patients. They found four major findings in their paper. Number one: XO expression was indeed higher in symptomatic carotid arteries. Number two: Symptomatic patients had a higher serum uric acid levels. Number three: Higher XO expression was inversely associated with the serum levels of HDL. Number four: The symptomatic plaques had higher amount of macrophages expressing XO. Dr. Negar Asdaghi:         Very interesting, but these findings were irrespective of the actual degree of luminal stenosis. In fact, the asymptomatic carotid plaques patients, as routine practice dictates, had a higher degree of luminal stenosis, but they had lower expression of XO and other associated findings. So what did we learn from this study? Well, there seems to be a strong association between certain biomarkers, in this case xanthine oxidase, and symptomatic state of carotid plaques, suggesting that perhaps in future we'll have other ways of measurements that may help us decide on carotid intervention rather than just the symptomatic state of the artery and the degree of stenosis. Dr. Negar Asdaghi:         It's been over 25 years since alteplase was approved as the thrombolytic agent of choice for treatment of patients with acute ischemic stroke. But in the past decade, tenecteplase, a genetically modified variant of alteplase with regulatory approval for treatment of ST-segment–elevation, myocardial infarction, has gained interest as an alternative reperfusion therapy for treatment of patients with acute ischemic stroke. Whether tenecteplase is ready to completely replace alteplase in clinical practice is certainly a burning question faced by the stroke community today. This was the subject of a lively debate at the most recent and entirely virtual 2021 International Stroke Conference, where a panel of experts reviewed the current evidence regarding the use of tenecteplase in acute ischemic stroke, examining data from animal models, preclinical studies to dose escalation studies and randomized trials, directly comparing tenecteplase with alteplase, as well as the collective clinical experience to date with this thrombolytic agent. Dr. Negar Asdaghi:         The proponents of change point out the many advantages of tenecteplase over alteplase, including its ease of use, increased fibrin specificity, longer half-time and its non-inferiority to alteplase in the head-to-head trials. On the other hand, the opponents caution stroke physicians, drawing attention to the inherent issues with the already completed clinical trials of tenecteplase, and argue that more data is needed before tenecteplase is considered as a thrombolytic agent of choice in routine clinical practice. Continuing on this debate in the September issue of the journal as part of the Controversies in Stroke series, Drs. Jeffrey Saver and May Nour provide opposing views to Drs. Dawn Kleindorfer and Mollie McDermott on the present evidence and current guidelines around tenecteplase use in acute ischemic stroke. Dr. Negar Asdaghi:         Acting as moderators, the senior authors of paper, Dr. Jukka Putaala, Head of Stroke Unit at Neurocenter, Helsinki University Hospital, and Dr. Markku Kaste, Emeritus Professor of Neurology at the University of Helsinki and past chairman of Neurocenter, Helsinki University Hospital, in Finland, provide us with the balancing remarks on the issue. I'm joined today by Professors Putaala and Kaste to give us an overview on the debate of tenecteplase versus alteplase. Is it time to make the switch? Good morning from sunny Florida and good afternoon to you both in Finland. Thank you for joining us on the podcast. I hope the weather is as beautiful in Helsinki today as it is here in Miami. Dr. Jukka Putaala:           Here it is not as warm as you have, but we have had a really beautiful summer, and at the moment, although it is also autumn, temperature is around 20 Celsius, so it's just great. Dr. Negar Asdaghi:         It's great to have you both. The paper outlines a generally recognized criteria to support the use of any new pharmacotherapy. Can you please start us off by reviewing the components of this criteria and tell us, please, how many checkmarks does TNK get on this checklist when considered as a reperfusion therapy in acute ischemic stroke? Dr. Jukka Putaala:           These eight criteria include a well-characterized mechanism of action; strong preclinical data; evidence of benefits and safety in a closely related clinical condition, which here is myocardial infarction; important practical advantages over existing agents; the clinical efficacy in how the patient has demonstrated in randomized trials; and endorsement by national practice guidelines. Also, support from regulatory authorities. And finally, clinical effectiveness, which has demonstrated in routine care. We think that tenecteplase for acute ischemic stroke meets actually all of these eight criteria. But we could also think that a smaller number of criteria will be enough to satisfy or meet, would be sufficient. Dr. Negar Asdaghi:         Perfect. So definitely many important steps, starting with the basics all the way to post-marketing clinical experience. Markku, now over to you. Can you remind us about the mechanism of action of tenecteplase? And what are some of the similarities and differences in terms of pharmacodynamic and pharmacokinetics with alteplase? Dr. Markku Kaste:           So alteplase catalyze plasminogen cleavage to plasmin and, in turn, degrades fibrin in thrombi, yielding clot lysis. TNK, compared to alteplase, is 14-fold greater fibrin activity and 80 times higher resistance to plasminogen activator inhibitor-1, which means it has a longer half-life, which is a major advantage. Patients need only one injection. In case you're compared to alteplase, when you had to have third dose injection and then one-hour infusion, which delay the care of patient, if the patient need thrombectomy. So it takes an hour for the infusion before patient can be transferred to thrombectomy, and time matters in brain infarction. So the faster you are, the better it is for patients. Dr. Negar Asdaghi:         Perfect. So more fibrin specificity, as you mentioned, and longer half-time for TNK. And in addition, TNK is not a new drug. In fact, there is over two decades' worth of experience with this in cardiology. Can you also tell us about this? And also some of the preclinical and animal studies that make TNK a potential candidate as a thrombolytic therapy in stroke? Dr. Markku Kaste:           In animal studies, both in vitro model of mural platelet deposits under arterial flow and a rabbit model using extracorporeal arterial-venous shunts, TNK was more potent, showing benefits up to three hours versus one hour when alteplase was used. So, it's a major benefit already in animal experiments and in the code team, of course, it will be transferred in clinical practice. So, in myocardial infarctions, in three randomized trials, including our 17,000 patients, TNK showed significant reduction for bleeding rates and similar intracerebral hemorrhage rates and 30-day mortality. Dr. Markku Kaste:           So, these facts support the use of TNK, also in ischemic stroke, the results from myocardial infarction, some steady encouraging. Although we have to keep in mind that myocardial infarction is very homogeneous disease, it's arterial occlusion, while ischemic stroke can be caused by the local occlusion just like myocardial infarction, but also from artery-to-artery thrombi or from a cardiac emboli. And these three [inaudible 00:17:43] mechanisms generate different kind of thrombi, so we need a better drug than alteplase, which really is effective, whatever is the etiology of the occlusion of brain artery. Dr. Negar Asdaghi:         Right. Thank you. Jukka, now over to you. Before we review the data from randomized trials of tenecteplase, can you please tell us about some of the practical advantages of tenecteplase over alteplase? We're comfortable with alteplase. Why should we make the switch? Dr. Jukka Putaala:           The key practical advantages arise from the fact that tenecteplase can be given as one single dose; it takes only one minute. And if you compare that to alteplase, you'll have to give the bolus first, and then following the bolus is 60 minutes infusion. And that also has many advantages in clinical practice, for example, if you have a patient with large vessel occlusion in a remote hospital, which is not thrombectomy-capable, you can give tenecteplase and then put the patient in the ambulance and transfer swiftly the patient to the thrombectomy center. While, when using alteplase, you have to start infusion, which you have to have the nursing staff that is capable of monitoring the infusion and taking care of any complications arising during the infusion and so forth. Dr. Jukka Putaala:           With tenecteplase, you can immediately transport the patient to a thrombectomy site after the bolus without any infusion-capable paramedics staff. Another practical advantage is that by using tenecteplase, you avoid the potential gap between the bolus and the infusion, which means that there is at least several minutes or longer gap in four out of five patients treated with alteplase. You can also think the other scenarios during this coronavirus era, and you have 15 patients with suspected or very fast coronavirus infection. By using bolus, you don't need to put nurses in the same room with the patients many times with the infusion if you use alteplase. Instead, you can use tenecteplase, it's only one single bolus, and you can go away and you don't have to be exposed to potential coronavirus infection. Dr. Negar Asdaghi:         So, many important advantages, as you mentioned. It seems very reasonable, then, to use tenecteplase in routine practice if it is indeed non-inferior to alteplase. Jukka, what dose of tenecteplase should be used for treatment of acute ischemic stroke patients? And we're definitely excited to hear about the head-to-head trials with tenecteplase versus alteplase. Dr. Jukka Putaala:           Well, the trial, the dose is 0.25 mg/kg or 0.4 mg/kg. It depends if you have LVO, if you review the evidence what we have now available, you have to use the lower dose in LVO patients. But you can use the higher dose in non-LVO patients. All of this arises from the evidence we have available right now. So, basically, five randomized trials have been completed, to date, comparing tenecteplase with alteplase in acute ischemic stroke. And shortly, if they pull out these five trials and compare primary outcome, which is modified Rankin Scale 0 to 1 versus prior, which means excellent outcome. Dr. Jukka Putaala:           So, when pulling out these five trials, 58% percent of patients rates excellent outcome versus 55% of alteplase, and this satisfied the criteria for non-inferiority. Regarding safety and secondary outcomes, major intracranial bleeding, mortality, this meta-analysis according to five trials shows similar results for tenecteplase and alteplase. You have to consider some details of this trial. I think Markku was going to quickly review some of the details of the science and doses used in these trials later on. Dr. Negar Asdaghi:         So, yes, this sounds great for tenecteplase, but so now over to you, Markku. As Jukka mentioned, do we hear a "not so fast for tenecteplase"? Is the current data enough to say goodbye to alteplase entirely and completely turn over to tenecteplase? What are some of the issues with the already completed trials? Dr. Markku Kaste:           It's not today, we cannot say goodbye to alteplase. As Jukka referred to those trials, there's no reason to go into these really deep details because the trials are quite small compared to ordinary clinical randomized trials studying stroke care. Like I don't want to give neuroprotection agents, for example. One larger trial was, let's say, reasonably well designed. But as to say that most of these trials are not really double-blind randomized clinical trials. And so the results which can be generated is not as reliable as double-blind trials because, of course, there are reasons, I mean, colleagues randomizing cases may think that, OK, a randomizing case and I'm not totally convinced about TNK. And I think this gentleman or this lady really needs effective thrombolytic agents, so I give alteplase, while if another patient with a mild symptom, same physician may think, OK, this stroke patient will recover no matter what, so let us randomize the patient. Dr. Markku Kaste:           So, it means these kind of unbalanced randomization provides data which is not really reliable. We had to have lots double-blinded randomized trials before it's time to say goodbye, if this double-blinded randomized trial verified that TNK beats alteplase. And, of course, we need also meta-analysis of those advanced trials, and these things can take time, although many guidelines, like AHA guidelines, European Stroke Organization guidelines, Chinese guidelines, Indian guidelines, they, in a way, how do you say, might recommend use of TNK, but I think we need more reliable scientific evidence before it's time to say goodbye to alteplase. Dr. Negar Asdaghi:         So, Jukka, Markku already alluded to this. I wanted you to review this for our listeners, the national practice guidelines and drug regulatory authority guidelines around the globe with regards to the issue of tenecteplase versus alteplase. Dr. Jukka Putaala:           Yeah, actually, already American, European, Chinese, Australian and Indian guidelines are recommending tenecteplase into the guidelines, which were recently published in 2019, between 2019 and 2021. What we can read from the guidelines is that tenecteplase can be considered over alteplase. But we have to remember that the strength of the recommendation will remain weak at present and quality of evidence is by the facts that we discussed of these five completely randomized trials and meta-analysis pulling out the data. Qualitative evidence remains slow, and, therefore, the wording in the guidelines is that it may be reasonable to choose or consider alteplase. Tenecteplase might be considered as an alternative to alteplase in certain conditions. Dr. Jukka Putaala:           The recommendations are a little bit mixed in the guidelines, but generally, in large vessel occlusions, the guidelines say that you could consider TNK over alteplase or even that you should consider TNK over alteplase in large vessel occlusion before proceeding to thrombectomy. However, in cases without large vessel occlusion, the statements are more mixed and they say tenecteplase might be considered or even that alteplase is preferred over tenecteplase until we have more evidence. Dr. Negar Asdaghi:         Thank you, Jukka. Markku, what should be our final takeaway message for the practicing stroke physicians at this point considering the use of tenecteplase in routine practice?   Dr. Markku Kaste:           Before your paper has been accepted and published in high-quality journal, it takes weeks, mostly it takes months, even a half a year. While in Stroke Conference, you get the most recent data, which is, let's say, generated last week or even the same day. So, when you want to really provide high-quality care of your patient, keep you updated. And then it's best for you and her, and it's better, of course, for your patient. International Stroke Conference and also European Stroke Conference, they are excellent places to get the most recent, yet unpublished, reliable information. Dr. Negar Asdaghi:         Professors Jukka Putaala and Markku Kaste, thank you for summarizing a large body of evidence for our listeners. We're definitely excited to learn how tenecteplase will ultimately stand against the old competitor and perhaps learn that both may be reasonable thrombolytic options, depending on the specifics of the clinical setting. Dr. Negar Asdaghi:         And this concludes our podcast for the September 2021 issue of Stroke. Please be sure to check the September table of contents for the full list of publications, including two special reports on consensus recommendations from the 11th STAIR Consortium, that is, Stroke Treatment Academic Industry Roundtable. Dr. Negar Asdaghi:         The first report is intended to enhance patient, clinician and policymaker comprehension at modified Rankin Scale findings in clinical trials and quality improvement initiatives. The second report from the STAIR Consortium is on top priorities for cerebroprotective studies, an important manuscript where the roundtable considered and presented a new paradigm for evaluation of putative therapies that may work together with recanalization treatments to improve outcome after ischemic stroke, with special attention to using the correct nomenclature, such as replacing the term "neuroprotection" with "cerebroprotection" when the intention of an investigation is to demonstrate that a new treatment benefits the entire brain, rather than neurons alone. Or replacing the term "time window" with "tissue window" or "target window" when selecting patients for recanalization therapies to enhance the notion that various elements of the neurovascular unit show vulnerability to ischemia evolving over different time scales in different brain regions. An important paradigm shift in ways we think of the brain under ischemic attack. With that, we invite you to continue to stay alert with Stroke Alert. Dr. Negar Asdaghi:         This program is copyright of the American Heart Association, 2021. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, visit AHAjournals.org.

Mit einem praktischen Beispiel aus dem Alltag einer Stroke Unit steigt Carina Schmid, Krankenschwester und Kommunikationscoach, in die heutige Folge von Born to Pflege ein. Denn das „Geschichten-Erzählen" ist für sie ein wichtiges Instrument, um zu erklären, dass es in Pflegeeinrichtungen ganz häufig um Regeln, um Strukturen und die Organisation an sich geht. Und weshalb genau deshalb vieles auch scheitert oder scheitern kann... Im Gespräch mit Tobias Gross zeigt sie, wie wir mit mehr Selbst-Mitgefühl eine andere Art von Gespräch mit anderen entwickeln können. Für mehr Frieden, Zusammenhalt und Freude im Pflegeteam! Carina Schmids Website: www.carinaschmid.com Facebook: https://www.facebook.com/borntopflege/ Instagram: https://instagram.com/borntopflege/ YouTube: https://www.youtube.com/channel/UCITRHJ4qllFPZkXaPDrlq6A Homepage: https://borntopflege.de/

As the world continues to reopen after a global pandemic, we check in and revisit Dr. Ronen Leker, the director of the Stroke Unit and The Peritz and Chantel Scheinberg Cerebrovascular Disease Research Laboratory at the Hadassah Medical Organization in Jerusalem. Dr. Leker is talking with host Benyamin Cohen about the link between stroke and COVID-19 long-haulers, stroke treatments and his research.

Podcaster senior: Dott. Paolo Cerrato Direttore Stroke Unit, Ospedale Molinette di TorinoPodcaster junior :Dott. Michele Romoli Neurologia e Stroke Unit, Ospedale "Bufalini", CesenaDottorando in Neuroscienze, Università di PerugiaPresentazione podcast:La gestione dell'ictus ischemico non inizia al momento dell'ospedalizzazione, ma dal momento stesso dell'evento. L'ictus è una patologia tempo-dipendente: l'ottimizzazione del primo soccorso è perciò fondamentale. Per questo motivo una sempre crescente attenzione viene dedicata all'organizzazione delle reti stroke, che hanno la funzione di convogliare i pazienti con ictus ischemico all'interno dei centri preposti al trattamento, seguendo due principi fondamentali: essere veloci, ed essere accurati

Fast jeder kennt jemanden, der schon mal einen Schlaganfall hatte. Und vielleicht war der eine oder andere von Euch sogar selbst betroffen. Kein Wunder: Schlaganfälle sind alles andere als selten. Das hat uns auch Dr. Peter Kühnlein bestätigt. Er ist kommissarischer Chefarzt der Neurologie in Coburg und Leiter der Stroke Unit. Also ein absoluter Spezialist für Schlaganfälle. Anja Hampel hat mit ihm gesprochen. www.radioeins.com

Welcome back to another episode of the ACN Podcast. In today's episode I speak with Skye Coote. Skye is a stroke nurse practitioner and nursing coordinator for the Mobile Stroke Unit (MSU) based out of the Royal Melbourne Hospital. In the first half of the episode Skye details the role and scope of practice for a stroke nurse practitioner within the hospital setting. In the second half Skye provides an overview of Australia's only Mobile Stroke Unit along with a detailed example of the type of patients the team responds to. Skye Coote: - Recent ACN Publication - Publications - Australian College of Nursing (acn.edu.au) - Twitter - @skyecoote For more details of the Mobile Stroke Unit: - Mobile Stroke Unit | The Royal Melbourne Hospital (thermh.org.au) - Melbourne Brain Centre | Mobile Stroke Unit (thembc.org.au)

Il secondo episodio di NEUROPOD tratterà le novità e i punti più salienti delle nuove linee guida SPREAD per le terapie di riperfusione nell'ictus ischemico cerebrale. Le nuove linee guida SPREAD incoraggiano il neurologo, sfruttando la lezione appresa dai grandi trials e dalla letteratura, a trattare sempre più pazienti in modo da ampliare la platea a cui può essere offerta questo ventaglio di opzioni terapeutiche che ha rivoluzionato il mondo della neurologia vascolare; sempre tenendo conto del fatto che si tratta di terapie tempo-dipendenti. Pertanto tali linee guide sono sempre più inclusive ma prevedono un'ottimale organizzazione pre e intraospedaliera al fine di garantire al numero più elevato di pazienti la terapia riperfusiva ideale nel tempo più breve possibile e assicurando i migliori outcomes funzionali.Podcaster senior: Prof. Danilo ToniDirettore UTN Policlinico Umberto IUniversità La Sapienza di RomaPodcaster junior : Dott. ssa Valentina ArnaoUO Neurologia e Stroke Unit, A. R. N. A. S. Ospedali Civico Di Cristina Benfratelli, Palermo

Der Arzt Dr. Dierk Heimann ist 46 Jahre alt, als ihn mitten in einem Vortrag der Schlag trifft. Seine linke Körperhälfte ist gelähmt, auf der rechten Seite das Schmerzempfinden fast erloschen. Die Chancen stehen neun zu eins gegen ihn. So wie ihm geht es jedes Jahr rund 200.000 Menschen in Deutschland.

Mobile stroke units, otherwise known as MSUs have recently been introduced in the care of patients suspected of having an acute stroke, leading to shortening in the time to thrombolytics, but how does the clinical effectiveness in terms of functional outcome and survival among patients treated in MSU and/or conventional care compare?  Carmen Lahiff-Jenkins; Managing Editor of the International Journal of Stroke spoke to the very impressive Dr Nida Fatima from the Department of Neurosurgery, Massachusetts General Hospital, Boston, USA who was the corresponding author for the Mobile Stroke Unit versus Standard Medical Care in the Management of patients with Acute Stroke: a systematic review and meta-analysis.   

Host: Interim President Michael Bernstein About Dr. Fiorella: Dr. David J. Fiorella, Director of the Stony Brook Cerebrovascular Center, Co-Director of the Stony Brook Cerebrovascular and Comprehensive Stroke Center, and Professor of Neurosurgery and Radiology joined the Department of Neurosurgery in 2009. Dr. Fiorella is considered a pioneer in the field of neuro-interventional therapies, advancing new devices and techniques for the treatment of Cerebrovascular disease. Dr. Fiorella spearheaded the acquisition of 2 Mobile Stroke units for Stony Brook University Hospital, the first program in Suffolk County. He is the Principle Investigator or Co-PI on numerous national trials evaluating new devices and techniques for the treatment of aneurysms, acute stroke and intracerebral hemorrhage. He is a senior member of the Society for Neuro-interventional Surgery (SNIS) and senior associate editor of the Journal of Neurointerventional Surgery. Dr. Fiorella has been named amongst the best interventional radiologists/endovascular surgeons in Castle Connolly's Top Doctors for several years in a row. About the Episode: Stony Brook Medicine Mobile Stroke Unit founder, Dr. David Fiorella, is considered a pioneer in the field of neuro-interventional therapies -- advancing new devices and techniques for the treatment of Cerebrovascular disease. He took that pioneering inspiration one step further in 2019 when he and a team of Stony Brook clinicians and colleagues launched the first two Mobile Stroke Units on Long Island. These Mobile Stroke Units enable stroke patients to be triaged and treated in the field, wherever the patient is located. Clinicians can administer IV TPa, a medication that minimizes brain injury, at any remote location and then immediately transport the patient to the closest appropriate care facility, where physicians can initiate further care. In this episode of “Beyond the Expected,” Michael Bernstein talks to Dr. Fiorella about his trajectory as a vascular brain surgeon and what inspired him to pursue the complex initiative of starting a Mobile Stroke Unit program. You'll also hear heartwarming stories of patient survival, and learn what this groundbreaking program has meant for Long Island stroke care since it launched in April 2019. Credits: Thanks to Dr. David Fiorella Guest Host: Michael Bernstein Executive Producer: Nicholas Scibetta Producer: Lauren Sheprow Art Director: Karen Leibowitz Assistant Producer: Emily Cappiello Assistant Producer: Joan Behan-Duncan Social Media: Meryl Altuch, Casey Borchick Podcast photography and YouTube Technician: Dennis Murray Podcast Director: Jan Diskin-Zimmerman Engineer/Technical Director: Phil Altiere Production Manager: Tony Fabrizio Camera/Lighting Director: Jim Oderwald Camera: Brian DiLeo Camera: Greg Klose Original score: “Mutti Bug” provided by Professor Tom Manuel Special thanks to the Stony Brook University School of Journalism for use of its podcast studio.

In this episode of Stroke and TBI Allies I would love to introduce a wonderful Nurse. Angela, works as a nurse on the new Stroke Unit at Northern Light Hospital, formally known as Eastern Maine Medical Center in Bangor, Maine. Angela also happens to be one of the founders of our stroke support groups that is held once a month in Brewer, Maine. for more details you can always message Marria and I, Emily, via e-mail at tbi.allies@gmail.com Angela is very inspiration and I really admire her not only as a nurse, but as a person as well. So come and listen to Angela give some great tips as well as her knowledge on how to better help Stroke and or TBI survivors! So the saying goes, we learn something new everyday! --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/emily-annis6/support

Aus dem Nichts: ein epileptischer Anfall. Der erste. Ein paar Wochen später - auch ohne Anmeldung: die erste mega Panikattacke. Du hast keine Ahnung, was da gerade in deinem Körper passiert. Du denkst: jetzt ist es vorbei. Im Krankenhaus setzen sie dich unter Strom. Es blinkt und pfeift. Sie schießen dich ab und alles verschwimmt im Nebel. Das war's wohl.

Wie ein Wunder empfindet es Dierk Heimann nach wie vor, dass er nach dem schweren Schlaganfall, der ihn mit nur 46 Jahren ereilte, heute wieder nahezu uneingeschränkt leben kann. Geholfen hat ihm eine schnelle Therapie auf einer Stroke Unit, sein eigenes medizinisches Wissen, sein Optimismus und sein Kampfgeist.

Kent county councillors have decided not to refer plans create three specialist stroke units back to the Secretary of State. Campaigners gathered outside County Hall earlier, urging them to change their minds. They're concerned patients living in Thanet and Medway will have to travel further for urgent care at the centres in Ashford, Dartford and Maidstone. https://www.kentonline.co.uk/

Kontakt & Infos: http://bit.ly/19TFVTg Ein Schlaganfall ist ein akuter Notfall. Durch den plötzlichen Verschluss eines Blutgefässes oder einer Blutung im Gehirn kommt es zur Zerstörung von Nervenzellen. Die Folge sind plötzliche Ausfallserscheinungen. Unsere 1997 eröffnete Spezialstation "Stroke Unit" ist ein Meilenstein in der Akutversorgung von Schlaganfallpatienten.

Prevenzione dell'ictus: Dott.ssa Francesca Romana Pezzella, Neurologo della Stroke Unit, Azienda Ospedaliera San Camillo Forlanini, Roma. Traumi alla spalla da sport: Dott. Carlo Felice De Biase, Responsabile U. O. S. Chirurgia Ortopedica e Traumatologia Arto Superiore, Ospedale San Carlo - IDI Sanità, Roma

Interview with Dr. Michael Hill, neurologist and Director of the Stroke Unit at the Foothills Hospital in Calgary, and Associate Professor of Clinical Neurosciences at the University of Calgary. In a review article published in CMAJ, Dr. Hill and colleagues compare ischemic stroke with acute coronary syndrome. Both are caused by sudden arterial occlusion and time to treatment is a critical factor affecting outcome. Stroke care should be designed around efficient, coordinated systems and dedicated care units to ensure the best possible outcomes. Full article (subscription required): www.cmaj.ca/lookup/doi/10.1503/cmaj.140355

Schlaganfall: jede Minute zählt Beim Schlaganfall ist Zeit der entscheidende Faktor. Je schneller dem Betroffenen geholfen wird, desto eher können dauerhafte Hirnschäden vermieden werden. Um die bestmögliche Versorgung zu gewährleisten, gibt es in der MHH eine Spezialabteilung nur für Schlaganfallpatienten: die Stroke Unit.

По традиции - лучшее за год: 2009Треки, которые всегда отлично шли на танцполах.. 1. Boogie Bros. - Fight for your right (Crystal Rock remix) 2. Snowdogs - My Heart Beats Electro (Ramon M meets Stroke Unit remix) 3. Sony Chan vs Mrak and Koba - Be a Renegade Star (Dj JIM Mashup 2 ver.) 4. PH Electro - San Francisco 5. Mr. Dan & Sparks - Body Slam (Rocket Pimp vocal remix) 6. House Rockerz ft. Unter Druck - Nur Tanzen 7. Disco Bitch - C'est Beau La Bourgeoisie 8. Spencer & Hill ft. Felguk - Fingertips (Spencer & Hill mix) 9. Gabry Ponte and Paki - Ocean Whispers (Hi-Fis nasty bass remix) 10. Omega - Mr. Vain 11. OLEG-OFF & JIM - PLAY HORMONE (electro extended) 12. Rocco - Everybody 9.0. (Elektrofachgeschaeft remix) 13. Mark Oh - United 14. Dot Com - Sexy Sound

По традиции - лучшее за год: 2009Треки, которые всегда отлично шли на танцполах.. 1. Boogie Bros. - Fight for your right (Crystal Rock remix) 2. Snowdogs - My Heart Beats Electro (Ramon M meets Stroke Unit remix) 3. Sony Chan vs Mrak and Koba - Be a Renegade Star (Dj JIM Mashup 2 ver.) 4. PH Electro - San Francisco 5. Mr. Dan & Sparks - Body Slam (Rocket Pimp vocal remix) 6. House Rockerz ft. Unter Druck - Nur Tanzen 7. Disco Bitch - C'est Beau La Bourgeoisie 8. Spencer & Hill ft. Felguk - Fingertips (Spencer & Hill mix) 9. Gabry Ponte and Paki - Ocean Whispers (Hi-Fis nasty bass remix) 10. Omega - Mr. Vain 11. OLEG-OFF & JIM - PLAY HORMONE (electro extended) 12. Rocco - Everybody 9.0. (Elektrofachgeschaeft remix) 13. Mark Oh - United 14. Dot Com - Sexy Sound

cue Tracklist: 1. PH Electro - San Francisco 2. Mr. Dan & Sparks - Body Slam (Rocket Pimp vocal remix) 3. Snowdogs - My Heart Beats Electro (Ramon M meets Stroke Unit remix) 4. Tune Up! - Feel Fine (Waveboy Electro mix) 5. Gigi Barocco & Ice MC - Think About the Way 2k9 (Spencer & Hill remix) 6. Nick Skitz - Release me (Disco Freaks club Mix) 7. G Adam vs Rammstein - Explosive Cocktail (Dj JIM Mash-Up mix) 8. Lazy Rich - Disco ballistic 9. Braincreator - What if 10. Delusion - Killer (Slipmatt and Rocket Pimp remix) 11. Comiccon - Open water (Mondo remix) 12. House Rockerz ft. Unter Druck - Nur Tanzen 13. Angger Dimas - Fight club (Rob Pix remix) 14. Aurum Beats - Girls 15. Cooler and Alex Long - Good time (club mix)

cue Tracklist: 1. PH Electro - San Francisco 2. Mr. Dan & Sparks - Body Slam (Rocket Pimp vocal remix) 3. Snowdogs - My Heart Beats Electro (Ramon M meets Stroke Unit remix) 4. Tune Up! - Feel Fine (Waveboy Electro mix) 5. Gigi Barocco & Ice MC - Think About the Way 2k9 (Spencer & Hill remix) 6. Nick Skitz - Release me (Disco Freaks club Mix) 7. G Adam vs Rammstein - Explosive Cocktail (Dj JIM Mash-Up mix) 8. Lazy Rich - Disco ballistic 9. Braincreator - What if 10. Delusion - Killer (Slipmatt and Rocket Pimp remix) 11. Comiccon - Open water (Mondo remix) 12. House Rockerz ft. Unter Druck - Nur Tanzen 13. Angger Dimas - Fight club (Rob Pix remix) 14. Aurum Beats - Girls 15. Cooler and Alex Long - Good time (club mix)